Logo image of JUNS

JUPITER NEUROSCIENCES INC (JUNS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:JUNS - US48208B2034 - Common Stock

1.02 USD
-0.06 (-5.48%)
Last: 12/31/2025, 8:11:02 PM
Fundamental Rating

1

Overall JUNS gets a fundamental rating of 1 out of 10. We evaluated JUNS against 191 industry peers in the Pharmaceuticals industry. JUNS has a bad profitability rating. Also its financial health evaluation is rather negative. JUNS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

JUNS had negative earnings in the past year.
JUNS had a negative operating cash flow in the past year.
JUNS had negative earnings in each of the past 5 years.
JUNS had a negative operating cash flow in each of the past 5 years.
JUNS Yearly Net Income VS EBIT VS OCF VS FCFJUNS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -1M -2M -3M -4M

1.2 Ratios

Looking at the Return On Assets, with a value of -148.65%, JUNS is doing worse than 85.86% of the companies in the same industry.
JUNS has a worse Return On Equity (-440.16%) than 78.53% of its industry peers.
Industry RankSector Rank
ROA -148.65%
ROE -440.16%
ROIC N/A
ROA(3y)-1786.7%
ROA(5y)-1258.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
JUNS Yearly ROA, ROE, ROICJUNS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K

1.3 Margins

JUNS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
JUNS Yearly Profit, Operating, Gross MarginsJUNS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K

More info and screens

2

2. Health

2.1 Basic Checks

JUNS has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, JUNS has more shares outstanding
The debt/assets ratio for JUNS has been reduced compared to a year ago.
JUNS Yearly Shares OutstandingJUNS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
JUNS Yearly Total Debt VS Total AssetsJUNS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2M 4M 6M

2.2 Solvency

Based on the Altman-Z score of -6.76, we must say that JUNS is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -6.76, JUNS is doing worse than 67.02% of the companies in the same industry.
A Debt/Equity ratio of 0.11 indicates that JUNS is not too dependend on debt financing.
JUNS has a Debt to Equity ratio (0.11) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Altman-Z -6.76
ROIC/WACCN/A
WACCN/A
JUNS Yearly LT Debt VS Equity VS FCFJUNS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 2M -2M 4M -4M -6M

2.3 Liquidity

A Current Ratio of 1.07 indicates that JUNS should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.07, JUNS is doing worse than 83.77% of the companies in the same industry.
JUNS has a Quick Ratio of 1.07. This is a normal value and indicates that JUNS is financially healthy and should not expect problems in meeting its short term obligations.
JUNS has a worse Quick ratio (1.07) than 77.49% of its industry peers.
Industry RankSector Rank
Current Ratio 1.07
Quick Ratio 1.07
JUNS Yearly Current Assets VS Current LiabilitesJUNS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2M 4M 6M

More info and screens

0

3. Growth

3.1 Past

JUNS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 46.67%, which is quite impressive.
EPS 1Y (TTM)46.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-800%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -73.25% on average over the next years. This is quite bad
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-420%
EPS Next 2Y78.89%
EPS Next 3Y-73.25%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
JUNS Yearly Revenue VS EstimatesJUNS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2025 2026 2027 2M 4M 6M 8M 10M
JUNS Yearly EPS VS EstimatesJUNS Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 0 -0.1 -0.2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for JUNS. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 16.67, JUNS is valued correctly.
Based on the Price/Forward Earnings ratio, JUNS is valued a bit cheaper than 79.06% of the companies in the same industry.
JUNS's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.13.
Industry RankSector Rank
PE N/A
Fwd PE 16.67
JUNS Price Earnings VS Forward Price EarningsJUNS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
JUNS Per share dataJUNS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 -0.05 -0.1 -0.15

4.3 Compensation for Growth

JUNS's earnings are expected to decrease with -73.25% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y78.89%
EPS Next 3Y-73.25%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for JUNS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

JUPITER NEUROSCIENCES INC

NASDAQ:JUNS (12/31/2025, 8:11:02 PM)

1.02

-0.06 (-5.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14 2025-11-14/amc
Earnings (Next)N/A N/A
Inst Owners3.95%
Inst Owner Change1602.22%
Ins Owners45.96%
Ins Owner Change0.08%
Market Cap35.12M
Revenue(TTM)N/A
Net Income(TTM)-5.90M
Analysts82.86
Price Target25.5 (2400%)
Short Float %0.24%
Short Ratio0.4
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-30.72%
Min EPS beat(2)-63.4%
Max EPS beat(2)1.96%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-16.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)-57.14%
Revenue NY rev (3m)-57.14%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 16.67
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 26.21
P/tB 26.21
EV/EBITDA N/A
EPS(TTM)-0.19
EYN/A
EPS(NY)0.06
Fwd EY6%
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS0
BVpS0.04
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -148.65%
ROE -440.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-1786.7%
ROA(5y)-1258.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.07
Quick Ratio 1.07
Altman-Z -6.76
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-800%
EPS Next Y-420%
EPS Next 2Y78.89%
EPS Next 3Y-73.25%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y20.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-714.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-714.93%
OCF growth 3YN/A
OCF growth 5YN/A

JUPITER NEUROSCIENCES INC / JUNS FAQ

What is the ChartMill fundamental rating of JUPITER NEUROSCIENCES INC (JUNS) stock?

ChartMill assigns a fundamental rating of 1 / 10 to JUNS.


Can you provide the valuation status for JUPITER NEUROSCIENCES INC?

ChartMill assigns a valuation rating of 1 / 10 to JUPITER NEUROSCIENCES INC (JUNS). This can be considered as Overvalued.


How profitable is JUPITER NEUROSCIENCES INC (JUNS) stock?

JUPITER NEUROSCIENCES INC (JUNS) has a profitability rating of 0 / 10.


What is the earnings growth outlook for JUPITER NEUROSCIENCES INC?

The Earnings per Share (EPS) of JUPITER NEUROSCIENCES INC (JUNS) is expected to decline by -420% in the next year.